[{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aragen Announces Expansion of Research Agreement with Boehringer Ingelheim","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Aragen Life Sciences"},{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocon Expands its Generic Formulations Portfolio with the Launch of Everolimus Tablets in the US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Biocon"},{"orgOrder":0,"company":"Immuneel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immuneel's CAR-T Cell Therapy Reports Positive In Early Phase-2 Trials In India","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Immuneel Therapeutics"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
IMN-003A (varnimcabtagene autoleucel) has demonstrated early, deep and durable remission in children and adults with relapsed / refractory B cell malignancies.
Everolimus tablets, a generic version of Afinitor® have been introduced in four strengths of 2.5mg, 5mg, 7.5mg and 10mg, with the 10 mg tablet used to treat certain types of cancers and tumours.
Xentuzumab* (BI 836845) is a humanized immunoglobulin G (IgG) 1 monoclonal antibody (mAb) that targets insulin-like growth factor (IGF) ligands IGF-1 and IGF-2 for treatment of breast cancer.